TRAW

Traws Pharma Inc

Add to Watchlist

Advanced Chart

1.950

-0.075(-3.704%)1D

Line

Candle

YTD

High

2.050

Open

2.010

VWAP

1.96

Vol

89.82K

Mkt Cap

13.90M

Low

1.900

Amount

176.33K

EV/EBITDA(TTM)

Total Shares

7.13M

814.37K

EV/OCF(TTM)

P/S(TTM)

2.87

Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q1

FY2024Q4

60.00K

+5.26%

60.00K

+7.14%

60.00K

+7.14%

Estimates Revision

The market is revising No Change the revenue expectations for Traws Pharma, Inc. (TRAW) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 30.00%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+30.00%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Traws Pharma Inc (TRAW.O) is -0.06, compared to its 5-year average forward P/E of -12.63. For a more detailed relative valuation and DCF analysis to assess Traws Pharma Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.63

Current PE

-0.06

Overvalued PE

35.86

Undervalued PE

-61.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.72

Current EV/EBITDA

-0.05

Overvalued EV/EBITDA

2.31

Undervalued EV/EBITDA

-3.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

187.63

Current PS

2.02

Overvalued PS

465.18

Undervalued PS

-89.91

Financials

Annual

Quarterly

FY2025Q2

YoY :

+4694.74%

2.73M

Total Revenue

FY2025Q2

YoY :

-78.77%

-1.25M

Operating Profit

FY2025Q2

YoY :

-99.26%

-915.00K

Net Income after Tax

FY2025Q2

YoY :

-99.91%

-0.11

EPS - Diluted

FY2025Q2

YoY :

-100.00%

N/A

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

N/A

FCF Margin - %

FY2025Q2

YoY :

-99.98%

-33.48

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

50.4K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

257.6K

Volume

Months

0-12

239.2K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

TRAW News & Events

Events Timeline

2025-10-14 (ET)

2025-10-14

07:07:59

Traws Pharma administers ratutrelvir to first patient in Phase 2 COVID trials

2025-08-18 (ET)

2025-08-18

07:03:07

Traws Pharma Granted Approval to Advance to Phase 2 COVID Research

2025-08-14 (ET)

2025-08-14

07:10:27

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

News

9.0

10-30PRnewswire

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

9.0

10-22Newsfilter

Dover, Delaware -- Expert Systems Inc. Backs Traws Pharma's Phase 2 Clinical Trials for Ratutrelvir, an Innovative Ritonavir-Free Antiviral Treatment for COVID-19.